" Hi xxxxxx,

Thank you for your question. Our clinical and business teams evaluated the NIH long Covid program when it was announced and determined that it would not be advantageous for ResverLogix to participate in the program. My understanding is that it would be very difficult –though perhaps not impossible– for a Canadian company to participate in the program, as it is intended primarily for American companies. The requirements for us accessing those funds would have meant cost increases to our planned Post COVID-19 Conditions trial in excess of the value of any funding NIH would have provided. 

Best regards,

Chris "